(Q40451346)

20 September 2017

Anti-JC virus antibody titres increase over time with natalizumab treatment. (English)

1 reference

20 September 2017

J Raffel

1

1 reference

20 September 2017

A R Gafson

series ordinal

2

1 reference

20 September 2017

O Malik

series ordinal

3

1 reference

20 September 2017

R Nicholas

series ordinal

4

1 reference

20 September 2017

8 October 2015

1 reference

Multiple Sclerosis Journal

20 September 2017

1 reference

20 September 2017

21

1 reference

20 September 2017

14

1 reference

20 September 2017

1833-1838

1 reference

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

20 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Asymptomatic reactivation of JC virus in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515599681

21 January 2018

Identifiers

DOI

10.1177/1352458515599681

1 reference

20 September 2017

1 reference